1. First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis
- Author
-
Sheng-Xi Wu, Shu-Han Yu, Jia-Zhou Lin, Xiao-Jian Wang, He-San Luo, Ze-Sen Du, and Xu-Yuan Li
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Combination therapy ,medicine.medical_treatment ,Immunology ,Network Meta-Analysis ,Programmed Cell Death 1 Receptor ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Immunology and Allergy ,Humans ,Lung cancer ,Adverse effect ,Neoplasm Staging ,Randomized Controlled Trials as Topic ,Chemotherapy ,business.industry ,Hazard ratio ,medicine.disease ,Survival Analysis ,Discontinuation ,030104 developmental biology ,Nivolumab ,030220 oncology & carcinogenesis ,Immunotherapy ,business - Abstract
Aim: To estimate efficacy of checkpoint inhibitors and rank treatment effects in non-small-cell lung cancer. Materials & methods: Prospective randomized trials were included. p-score was used to rank treatment effects. Results: A total of nine trials were identified, involving 5504 patients and three checkpoint inhibitors. Pembrolizumab plus chemotherapy had the highest p-score of 0.95 among all the treatments, and was superior to pembrolizumab alone (hazard ratio: 0.87; 95% CI: 0.79–0.95). Combination therapy had more grade 3–5 adverse events; but toxicity-related discontinuation and treatment-related death did not increase. Conclusion: Pembrolizumab plus chemotherapy was likely to be the most effective treatment for patients with wild-type advanced NSCLC.
- Published
- 2019